Stock comparison
ELI LILLY & Co is 535.0x more valuable than Syndax Pharmaceuticals Inc by market capitalization ($1.119 T vs $2.09 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
LLY is larger
ELI LILLY & Co is 535.0x more valuable than Syndax Pharmaceuticals Inc by market capitalization ($1.119 T vs $2.09 B).
Market value leader
LLY
ELI LILLY & Co is 535.0x more valuable than Syndax Pharmaceuticals Inc by market capitalization ($1.119 T vs $2.09 B).
Revenue leader
LLY
SNDX: $172.35M vs LLY: $65.18B.
Profit leader
LLY
SNDX: -$285.40M vs LLY: $20.64B.
Margin leader
LLY
SNDX: -165.6% vs LLY: 31.7% net margin.
| Metric | SNDX | LLY |
|---|---|---|
| Market cap | $2.09 B | $1.119 T |
| US-listed rank | #2095 | #10 |
| Revenue (latest FY) | $172.35M | $65.18B |
| Net income (latest FY) | -$285.40M | $20.64B |
| Net margin | -165.6% | 31.7% |
| P/E (trailing FY) | - | 54.2x |
| SEC filings | 635 | 1,000 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
ELI LILLY & Co is 535.0x more valuable than Syndax Pharmaceuticals Inc by market capitalization ($1.119 T vs $2.09 B).
In their latest fiscal years, Syndax Pharmaceuticals Inc reported $172.35M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Syndax Pharmaceuticals Inc and ELI LILLY & Co, or browse the full rankings.